Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

This publication has 14 references indexed in Scilit:

• Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients
  British Journal of Haematology, 2002
• Hyperploidy induced by drugs that inhibit formation of microtubule promotes chromosome instability
  Genes to Cells, 2002
• Docetaxel Versus Paclitaxel for Antiangiogenesis
  Journal of Hematotherapy & Stem Cell Research, 2002
• Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
  Journal of Clinical Oncology, 1999
• Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
  Journal of Clinical Oncology, 1998
• Angiogenesis spectrum in the stroma of B‐cell non‐Hodgkin's lymphomas. An immunohistochemical and ultrastructural study
  European Journal of Haematology, 1996
• Expression of Tenascin is Related to Histologic Malignancy and Angiogenesis in B-Cell non-Hodgkin's Lymphomas
  Leukemia & Lymphoma, 1996
• Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A review
  Clinical Oncology, 1994
• PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)
  Annals of Oncology, 1991
• National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usage
  Cancer, 1982